Milestone Pharmaceuticals (NASDAQ:MIST) Earns Buy Rating from HC Wainwright

HC Wainwright restated their buy rating on shares of Milestone Pharmaceuticals (NASDAQ:MISTFree Report) in a report released on Thursday, Benzinga reports. They currently have a $25.00 target price on the stock.

Separately, Piper Sandler dropped their price objective on shares of Milestone Pharmaceuticals from $6.00 to $5.00 and set an overweight rating for the company in a research note on Tuesday, March 5th.

Read Our Latest Research Report on Milestone Pharmaceuticals

Milestone Pharmaceuticals Stock Performance

Milestone Pharmaceuticals stock opened at $1.74 on Thursday. The company has a debt-to-equity ratio of 1.27, a current ratio of 22.75 and a quick ratio of 10.11. Milestone Pharmaceuticals has a fifty-two week low of $1.33 and a fifty-two week high of $4.39. The stock’s fifty day moving average is $1.67 and its two-hundred day moving average is $1.96.

Milestone Pharmaceuticals (NASDAQ:MISTGet Free Report) last issued its quarterly earnings data on Thursday, March 21st. The company reported ($0.32) EPS for the quarter, missing analysts’ consensus estimates of ($0.30) by ($0.02). Sell-side analysts forecast that Milestone Pharmaceuticals will post -0.79 EPS for the current fiscal year.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Milestone Pharmaceuticals stock. BNP Paribas Financial Markets lifted its position in shares of Milestone Pharmaceuticals Inc. (NASDAQ:MISTFree Report) by 177.0% during the 1st quarter, according to its most recent disclosure with the SEC. The firm owned 16,900 shares of the company’s stock after buying an additional 10,800 shares during the period. BNP Paribas Financial Markets’ holdings in Milestone Pharmaceuticals were worth $30,000 as of its most recent SEC filing. 86.18% of the stock is owned by institutional investors and hedge funds.

About Milestone Pharmaceuticals

(Get Free Report)

Milestone Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate.

Recommended Stories

Receive News & Ratings for Milestone Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Milestone Pharmaceuticals and related companies with's FREE daily email newsletter.